| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| NAGENiagen Bioscience Inc | 503.58M | 6.31 | 57.36 | 19.18% | 16.38% | 28.91% | 2.37% | 0.06 |
| BTXBlackRock Technology and Private Equity Term Trust | 808.8M | 6.93 | 40.76 | -81.13% | 87.75% | 1.87% | 34.27% | |
| HALOHalozyme Therapeutics, Inc. | 8.45B | 71.82 | 20.94 | 22.44% | 47.91% | 118.17% | 5.55% | 4.14 |
| RPRXRoyalty Pharma plc | 16.97B | 39.72 | 20.80 | -3.86% | 32.55% | 7.95% | 16.32% | 0.74 |
| REGNRegeneron Pharmaceuticals, Inc. | 76.63B | 741.92 | 19.35 | 8.27% | 32.13% | 14.79% | 4.78% | 0.09 |
| GMABGenmab A/S | 20.85B | 33.85 | 2.79 | 30.67% | 46.8% | 114.25% | 36.37% | 0.03 |
| DNAGinkgo Bioworks Holdings, Inc. | 464.86M | 9.58 | -0.91 | -9.71% | -188% | -60.66% | 0.65 | |
| PRMEPrime Medicine, Inc. | 720.24M | 3.99 | -2.42 | -33.02% | -121.95% | 0.27 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 4.8K | 124.4K | 165.5K | 164.5K | 87.75K | 88.6K | 9K | 11K |
| Revenue Growth % | - | - | - | 24.92% | 0.33% | -0.01% | -0.47% | 0.01% | -0.9% | 0.22% |
| Cost of Goods Sold | 0 | 766.07K | 8K | 70.38K | 45.5K | 50.6K | 47.95K | 28.49K | 3.6K | 4.4K |
| COGS % of Revenue | - | - | 1.67% | 0.57% | 0.27% | 0.31% | 0.55% | 0.32% | 0.4% | 0.4% |
| Gross Profit | 0 | -766.07K | -3.2K | 54.02K | 120K | 113.9K | 39.8K | 60.11K | 5.4K | 6.6K |
| Gross Margin % | - | - | -0.67% | 0.43% | 0.73% | 0.69% | 0.45% | 0.68% | 0.6% | 0.6% |
| Gross Profit Growth % | - | - | 1% | 17.88% | 1.22% | -0.05% | -0.65% | 0.51% | -0.91% | 0.22% |
| Operating Expenses | 20.83K | 759.67K | 1.17M | 1.17M | 1.25M | 1.23M | 3.17M | 10.3M | 5.63M | 5.75M |
| OpEx % of Revenue | - | - | 244.71% | 9.39% | 7.55% | 7.47% | 36.08% | 116.3% | 625.06% | 522.77% |
| Selling, General & Admin | 20.83K | 664.98K | 898.53K | 1.05M | 1.22M | 1.16M | 2.96M | 3.94M | 3.56M | 3.24M |
| SG&A % of Revenue | - | - | 187.19% | 8.44% | 7.39% | 7.06% | 33.78% | 44.51% | 395.59% | 294.48% |
| Research & Development | 0 | 85.33K | 260.08K | 96.62K | 0 | 0 | 109.18K | 6.27M | 1.97M | 2.4M |
| R&D % of Revenue | - | - | 54.18% | 0.78% | - | - | 1.24% | 70.75% | 218.96% | 218.25% |
| Other Operating Expenses | 0 | 9.36K | 0 | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K |
| Operating Income | -20.83K | -766.07K | -1.18M | -1.11M | -1.13M | -1.11M | -3.13M | -10.24M | -5.62M | -5.74M |
| Operating Margin % | - | - | -245.38% | -8.96% | -6.83% | -6.78% | -35.62% | -115.62% | -624.46% | -522.17% |
| Operating Income Growth % | -0.07% | -35.78% | -0.54% | 0.05% | -0.01% | 0.01% | -1.8% | -2.28% | 0.45% | -0.02% |
| EBITDA | -20.83K | -756.72K | -1.16M | -1.09M | -1.1M | -1.05M | -3.03M | -10.15M | -5.53M | -5.63M |
| EBITDA Margin % | - | - | -242.04% | -8.79% | -6.67% | -6.37% | -34.57% | -114.59% | -613.95% | -512.13% |
| EBITDA Growth % | -0.07% | -35.33% | -0.54% | 0.06% | -0.01% | 0.05% | -1.89% | -2.35% | 0.46% | -0.02% |
| D&A (Non-Cash Add-back) | 0 | 9.36K | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K |
| EBIT | -20.83K | -759.67K | -1.18M | -12.29M | -6.59M | -35.1M | 23.49M | -10.24M | -5.62M | -5.74M |
| Net Interest Income | 0 | 0 | -377.59K | -1.36M | -1.9M | -1.23M | -4.28M | 100.33K | 333.56K | 250.38K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100.33K | 333.56K | 250.38K |
| Interest Expense | 9.93K | 6.4K | 377.59K | 1.36M | 1.9M | 1.23M | 4.28M | 0 | 0 | 0 |
| Other Income/Expense | -9.93K | -6.4K | -1.48M | -12.54M | -7.35M | -35.21M | 22.34M | 100.33K | 333.56K | 250.38K |
| Pretax Income | -30.76K | -766.07K | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M |
| Pretax Margin % | - | - | -553.98% | -109.77% | -51.26% | -220.82% | 218.93% | -114.49% | -587.4% | -499.41% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -30.76K | -766.07K | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M |
| Net Margin % | - | - | -553.98% | -109.77% | -51.26% | -220.82% | 218.93% | -114.49% | -587.4% | -499.41% |
| Net Income Growth % | -0.1% | -23.9% | -2.47% | -4.14% | 0.38% | -3.28% | 1.53% | -1.53% | 0.48% | -0.04% |
| Net Income (Continuing) | -30.76K | -766.07K | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1281.71 | -5471.94 | -17379.79 | -11351.33 | -5017.67 | -626.88 | 56.10 | -9.28 | -3.76 | -3.71 |
| EPS Growth % | -0.1% | -3.27% | -2.18% | 0.35% | 0.56% | 0.88% | 1.09% | -1.17% | 0.59% | 0.01% |
| EPS (Basic) | -1281.71 | -5471.94 | -17379.79 | -11351.33 | -5017.67 | -626.88 | 73.75 | -9.28 | -3.76 | -3.71 |
| Diluted Shares Outstanding | 24 | 140 | 153 | 1.2K | 2.07K | 57.95K | 324.86K | 1.09M | 1.41M | 1.48M |
| Basic Shares Outstanding | 24 | 140 | 153 | 1.2K | 2.07K | 57.95K | 260.5K | 1.09M | 1.41M | 1.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 216 | 221.87K | 18.5K | 313.66K | 94.25K | 98.01K | 10.74M | 18.75M | 10.27M | 6.14M |
| Cash & Short-Term Investments | 216 | 221.87K | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 18.4M | 9.99M | 5.94M |
| Cash Only | 216 | 221.87K | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 8.32M | 3.47M | 5.94M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.08M | 6.52M | 0 |
| Accounts Receivable | 0 | 0 | 4.8K | 9.6K | 5.6K | 0 | 2.48K | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | 365.08 | 28.17 | 12.35 | - | 10.34 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 10.87K | 10.19K | 6.59K | 2.19K |
| Days Inventory Outstanding | - | - | - | - | - | - | 82.71 | 130.6 | 668.56 | 182 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 277.25K | 192.71K |
| Total Non-Current Assets | 0 | 100.64K | 184.65K | 163.5K | 436.56K | 619.76K | 530.96K | 438.88K | 444.29K | 533.84K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 100.64K | 184.65K | 163.5K | 436.56K | 619.76K | 527.68K | 435.6K | 441.01K | 530.56K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 3.28K | 3.28K | 3.28K | 3.28K |
| Total Assets | 216 | 322.51K | 203.15K | 477.16K | 530.8K | 717.77K | 11.27M | 19.19M | 10.72M | 6.67M |
| Asset Turnover | - | - | 0.02x | 0.26x | 0.31x | 0.23x | 0.01x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | -0.77% | 1492.11% | -0.37% | 1.35% | 0.11% | 0.35% | 14.7% | 0.7% | -0.44% | -0.38% |
| Total Current Liabilities | 157.82K | 453.86K | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K |
| Accounts Payable | 17.08K | 66.39K | 237.57K | 331.84K | 320.79K | 350.9K | 761.86K | 3.27M | 317.28K | 273.53K |
| Days Payables Outstanding | - | 31.63 | 10.84K | 1.72K | 2.57K | 2.53K | 5.8K | 41.86K | 32.17K | 22.69K |
| Short-Term Debt | 140.74K | 102.6K | 501.75K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 2.6K | 375.89K | 10.8K | 371.37K | 639.35K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1.31M | 3.24M | 6.48M | 38.58M | 0 | 0 | 0 | 0 |
| Current Ratio | 0.00x | 0.49x | 0.01x | 0.07x | 0.01x | 0.00x | 10.22x | 5.64x | 27.65x | 18.73x |
| Quick Ratio | 0.00x | 0.49x | 0.01x | 0.07x | 0.01x | 0.00x | 10.21x | 5.64x | 27.64x | 18.72x |
| Cash Conversion Cycle | - | - | - | - | - | - | -5.71K | - | - | - |
| Total Non-Current Liabilities | 26.2K | 26.44K | 4.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 26.2K | 25K | 915 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 1.44K | 3.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 184.02K | 480.3K | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K |
| Total Debt | 166.94K | 125K | 513.46K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 |
| Net Debt | 166.72K | -96.87K | 499.77K | 378K | 973.62K | 690.69K | -10.72M | -8.32M | -3.47M | -5.94M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -2.10x | -119.74x | -3.12x | -0.82x | -0.60x | -0.91x | -0.73x | - | - | - |
| Total Equity | -183.8K | -157.79K | -2.24M | -3.99M | -8.07M | -39.8M | 10.22M | 15.86M | 10.34M | 6.34M |
| Equity Growth % | -0.2% | 0.14% | -13.17% | -0.79% | -1.02% | -3.93% | 1.26% | 0.55% | -0.35% | -0.39% |
| Book Value per Share | -7658.50 | -1127.08 | -14615.51 | -3320.56 | -3903.05 | -686.90 | 31.45 | 14.51 | 7.35 | 4.28 |
| Total Shareholders' Equity | -183.8K | -157.79K | -2.24M | -3.99M | -8.07M | -39.8M | 10.22M | 15.86M | 10.34M | 6.34M |
| Common Stock | 18.11K | 105.01K | 114.8K | 902.71K | 22.49K | 768.54K | 6.34K | 1.41K | 1.43K | 1.75K |
| Retained Earnings | -356.1K | -766.57K | -3.43M | -17.08M | -25.57M | -61.89M | -43.67M | -53.81M | -59.1M | -64.59M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -270.95K | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -14.64K | -445.23K | -889.62K | -1.05M | -1.21M | -434.56K | -2.22M | -7.8M | -8.03M | -5.3M |
| Operating CF Margin % | - | - | -185.34% | -8.46% | -7.33% | -2.64% | -25.25% | -88% | -891.99% | -481.94% |
| Operating CF Growth % | 0.15% | -29.42% | -1% | -0.18% | -0.15% | 0.64% | -4.1% | -2.52% | -0.03% | 0.34% |
| Net Income | -30.76K | -766.07K | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M |
| Depreciation & Amortization | 0 | 9.36K | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K |
| Stock-Based Compensation | 0 | 2.56K | 144.16K | 1.88K | 0 | 170.32K | 595.38K | 68.75K | 36.65K | 36.65K |
| Deferred Taxes | 0 | -2.56K | 347.56K | 11.19M | 0 | 33.98M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 2.56K | 1.1M | 1.26M | 7.18M | 979.96K | -22.36M | 0 | -34.09K | 0 |
| Working Capital Changes | 16.12K | 308.92K | 158.06K | 129.43K | 62.2K | 692.79K | 249.47K | 2.19M | -2.84M | 45.09K |
| Change in Receivables | 0 | 0 | -4.8K | -4.8K | 4K | 5.6K | -2.48K | 2.48K | 0 | 0 |
| Change in Inventory | 0 | 0 | 2.41M | 4.2M | 0 | 0 | -10.87K | 672 | 3.6K | 4.4K |
| Change in Payables | 6.89K | 22.6K | 171.18K | 94.76K | -11.05K | 30.11K | 410.96K | 2.51M | -2.95M | -43.85K |
| Cash from Investing | 0 | -10K | 0 | 0 | 0 | -250K | 0 | -10.08M | 3.45M | 6.32M |
| Capital Expenditures | 0 | -10K | 0 | 0 | 0 | -250K | 0 | 0 | -100K | -200K |
| CapEx % of Revenue | - | - | - | - | 0% | 1.52% | - | - | 11.11% | 18.18% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -10K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 13.9K | 677K | 681.45K | 1.34M | 997.68K | 693.92K | 12.84M | 15.47M | -270.95K | 1.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 552K | 108.2K | 0 | 0 | 0 | -548.31K | 457 | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -14.64K | -455.23K | -889.62K | -1.05M | -1.21M | -684.56K | -2.22M | -7.8M | -8.13M | -5.3M |
| FCF Margin % | - | - | -185.34% | -8.46% | -7.33% | -4.16% | -25.25% | -88% | -903.1% | -481.94% |
| FCF Growth % | 0.15% | -30.1% | -0.95% | -0.18% | -0.15% | 0.44% | -2.24% | -2.52% | -0.04% | 0.35% |
| FCF per Share | -609.92 | -3251.66 | -5814.52 | -874.70 | -586.60 | -11.81 | -6.82 | -7.13 | -5.77 | -3.58 |
| FCF Conversion (FCF/Net Income) | 0.48x | 0.58x | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 9.19K | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | - | - | 188.02% | -77.78% | -40.34% | -65.85% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | -218.34% | -58.46% | -118.38% |
| Gross Margin | - | - | -66.67% | 43.43% | 72.51% | 69.24% | 45.36% | 67.84% | 60% | 60% |
| Net Margin | - | - | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% |
| Interest Coverage | -2.10x | -119.74x | -3.12x | -0.82x | -0.60x | -0.91x | -0.73x | - | - | - |
| FCF Conversion | 0.48x | 0.58x | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x |
| Revenue Growth | - | - | - | 2491.67% | 33.04% | -0.6% | -46.65% | 0.96% | -89.84% | 22.22% |
Creative Medical Technology Holdings, Inc. (CELZ) reported $0.0M in revenue for fiscal year 2024.
Creative Medical Technology Holdings, Inc. (CELZ) grew revenue by 22.2% over the past year. This is strong growth.
Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $6.0M for fiscal year 2024.
Creative Medical Technology Holdings, Inc. (CELZ) has a return on equity (ROE) of -65.8%. Negative ROE indicates the company is unprofitable.
Creative Medical Technology Holdings, Inc. (CELZ) had negative free cash flow of $5.9M in fiscal year 2024, likely due to heavy capital investments.